Get access

Development of a targeted risk-group model for skin cancer screening based on more than 100 000 total skin examinations


  • Conflict of interest
    We declare that we have no conflict of interest. None of the authors has received any research grants, honoraria, consulting fees, advisory board fees, lecture fees or paid advisory fees from BKK. None of the authors are employees or shareholders in BKK.

  • Bayerische Betriebskrankenkassen (BKK) sponsored the data entry and statistical analysis.

  • This study was conducted for BKK medical insurance.

S. Guther.


Background  Skin cancer screening aims to detect potentially metastasizing skin cancers at an early and surgically curable stage. This may take the form of mass screening, as currently occurs in Germany, or of targeted screening of those at greatest risk.

Objective  To develop a model to identify patients at high risk of developing skin cancer who would benefit from regular skin cancer screening.

Methods  This was an open prospective point-prevalence study of consecutive patients presenting to dermatologists for a total skin check. Demographic and skin cancer risk factors were recorded and, for the first time, histology of skin lesions was documented. Results were analysed by univariate and multivariate analyses and, after logistic regression with stepwise forward selection, a risk-group model was developed.

Results  The results of 108 281 total skin examinations were available for analysis. 142 definite melanomas, 108 severely dysplastic naevi/cannot-exclude-melanoma, 491 basal cell carcinomas (BCC) and 93 squamous cell carcinomas (SCC) were excised. A risk model was developed for melanoma and SCC based on mathematical e-functions. The model had >92% sensitivity for melanoma and SCC and an overall 67.24% specificity for melanoma, SCC and BCC. This targeted risk model identified one-third of the study population as being at risk for the development of melanoma and SCC.

Conclusions  Using the risk calculator developed from this study, targeted screening of the identified at-risk population reduces the numbers needed to be screened regularly by 50%, yet has better sensitivity for melanoma and similar sensitivity for SCC compared to the current mass screening programme in Germany.